BPC May 03 update

Alnylam ALNY shares lower on Sanofi SNY exit; Micro-cap Durect DRRX +49% on upcoming data release

Price and Volume Movers

AstraZeneca PLC (NYSE: AZN) announced the approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D).

Alnylam Pharmaceuticals (NASDAQ:ALNY) shares closed down 6% to $77.29 following reports that Sanofi (NASDAQ: SNY) is selling its stake in the company. This follows news in early April that the companies agreed to conclude their five-year alliance in rare genetic diseases.

DURECT Corporation (Nasdaq: DRRX) shares closed up 49% to $0.79 following news the microcap will report preliminary data from its Phase 2 trial of DUR-928 in patients with alcoholic hepatitis (AH), after the market close on Tuesday, May 7.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

IMV Inc. (IMV): $4.40; +19%.

Idera Pharmaceuticals, Inc. (IDRA): $3.57; +17%.

Anika Therapeutics, Inc. (ANIK): $39.22; +15%.

ImmunoGen, Inc. (IMGN): $2.88; +15%.

Sienna Biopharmaceuticals, Inc. (SNNA): $1.97; +13%.

DECLINERS:

Diffusion Pharmaceuticals Inc. (DFFN): $4.59; -22%.

ARCA biopharma, Inc. (ABIO): $10.90; -14%.

Emergent BioSolutions Inc. (EBS): $48.12; -10%.

Auris Medical Holding Ltd. (EARS): $4.82; -6%.

Seres Therapeutics, Inc. (MCRB): $5.04; -6%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ATNX – Athenex Inc.
Oraxol
Angiosarcoma

Phase 1 Phase 1 preliminary data released May 3, 2019. 3/7 complete responses.
$1.1 billion

AZN – Astrazeneca PLC
Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride)
Type 2 diabetes

Approved FDA approval announced May 3, 2019.
$99.4 billion

DRRX – DURECT Corporation
DUR-928
Alcoholic hepatitis (AH)

Phase 2 Phase 2 preliminary data noted May 8, 2019.
$116.4 million

IMGN – ImmunoGen Inc.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer

Phase 1/2 Phase 1b/2 presentation at ASCO June 1, 2019, 4:30pm.
$291.6 million

IMGN – ImmunoGen Inc.
IMGN632
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Phase 1 Phase 1 updated data due 2019.
$291.6 million

IMV – IMV Inc.
DPX-Survivac and pembrolizumab
Diffuse Large Cell Lymphoma

Phase 2 Phase 2 top-line data due June 12, 2019 at ICML.
$197.3 million

NVO – Novo Nordisk A/S
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes

Phase 2 Phase 2 data due 2Q 2019.
$113 billion

NVO – Novo Nordisk A/S
Somapacitan
Growth Hormone Deficiency (GHD)

Phase 3 Phase 3 trial to be initiated 2Q 2019.
$113 billion

NVO – Novo Nordisk A/S
Concizumab
Hemophilia A

Phase 2 Phase 3 trial to be initiated 3Q 2019.
$113 billion

NVO – Novo Nordisk A/S
LAI287
Type 2 diabetes

Phase 2 Phase 2 data due 4Q 2019.
$113 billion

ONCY – Oncolytics Biotech Inc.
Pelareorep and Tecentriq - AWARE-1
Breast cancer

Phase 1b Phase 1b interim data due 2H 2019.
$34.3 million

ONCY – Oncolytics Biotech Inc.
Pelareorep with Keytruda
Multiple myeloma

Phase 2 Phase 2 trial to be initiated mid-2019.
$34.3 million

RYTM – Rhythm Pharmaceuticals Inc.
Setmelanotide
POMC deficiency obesity

Phase 3 Phase 3 initial data due 3Q 2019.
$956.2 million

RYTM – Rhythm Pharmaceuticals Inc.
Setmelanotide
Leptin Receptor Deficiency Obesity

Phase 3 Phase 3 top-line data due 3Q 2019.
$956.2 million

RYTM – Rhythm Pharmaceuticals Inc.
Setmelanotide
Alstrom Syndrome and Bardet-Biedl Syndrome

Phase 3 Phase 3 data due 2020.
$956.2 million